Your Health, We Care
Finerenone is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
来自FDA，2022.09
This article analyzes the clinical application and economic cost of finerenone.W···【more】
Release date：2025-04-15Recommended：33
According to the treatment needs of patients with specific chronic diseases, the···【more】
Release date：2025-04-15Recommended：31
In view of the application value and clinical practice of finerenone, this artic···【more】
Release date：2025-04-14Recommended：37
